|
Subgroups
|
No. of studies
|
OR
|
95 % CI
|
P value
|
Heterogeneity (I2)
|
|---|
|
Clinical node status
|
|
Negative
|
14
|
2.56
|
1.88–3.49
|
<0.05
|
48.7
|
|
Positive
|
1
|
1.42
|
0.68–2.96
|
>0.05
|
–
|
|
Mixed
|
4
|
1.93
|
0.99–3.76
|
>0.05
|
59.5
|
|
NAC
|
|
Before NAC
|
6
|
2.96
|
1.78–4.94
|
<0.05
|
15.6
|
|
After NAC
|
3
|
1.53
|
0.94–2.47
|
>0.05
|
31.6
|
|
Proportion of patients with positive LSG
|
|
≥ 90 %
|
7
|
1.41
|
0.83–2.39
|
>0.05
|
22.1
|
|
< 90 %
|
6
|
2.99
|
1.99–4.48
|
<0.05
|
42.8
|
|
Data source
|
|
RCT
|
6
|
2.25
|
1.23–4.11
|
<0.05
|
74.7 %
|
|
NPS
|
18
|
1.96
|
1.40–2.74
|
<0.05
|
62.5 %
|
|
Sample size
|
|
> 300
|
15
|
2.01
|
1.42–2.84
|
<0.05
|
75.9 %
|
|
< 300
|
9
|
2.01
|
1.28–3.15
|
<0.05
|
7.0 %
|
|
Location
|
|
USA
|
8
|
1.33
|
0.82–2.16
|
>0.05
|
80.1 %
|
|
Europe
|
11
|
2.48
|
1.60–3.84
|
<0.05
|
43.7 %
|
|
Asia
|
5
|
2.93
|
2.05–4.19
|
<0.05
|
1.3 %
|
|
Injection site of blue dye
|
|
Superficial
|
10
|
1.95
|
0.93–4.08
|
>0.05
|
70.6 %
|
|
Deep
|
9
|
2.76
|
2.32–3.30
|
<0.05
|
0
|
|
Injection site of radioisotope
|
|
Superficial
|
9
|
2.05
|
0.87–4.84
|
>0.05
|
76.0 %
|
|
Deep
|
11
|
2.55
|
1.93–3.37
|
<0.05
|
31.2 %
|
-
LSG lymphoscintigraphy, NAC neoadjuvant chemotherapy
